Anti–Peptidylarginine Deiminase 4 Autoantibodies and Disease Duration as Predictors of Treatment Response in Rheumatoid Arthritis
ACR Open Rheumatology · 2024-02 · 6 (2) · 81-90
DOI: 10.1002/acr2.11630 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACR Open Rheumatology, online erschienen am 07.12.2023. Verfasst von Laura C Cappelli und 4 weiteren Autor:innen. Beteiligte Einrichtung: Johns Hopkins School of Medicine, Baltimore, Maryland. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAMS NIH HHS, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Pfizer.
Abstract (Originalsprache)
Background
Given that autoantibodies to peptidylarginine deiminase 4 (PAD4) are associated with erosive disease in established rheumatoid arthritis (RA), this study was conducted to compare the clinical and prognostic use of anti‐PAD4 antibodies in patients with early and established RA.
Methods
Sera from patients with early (duration
Autor:innen und Institutionen
- Johns Hopkins School of Medicine, Baltimore, Maryland.
ORCID-Profile: Laura C Cappelli, Clifton O Bingham, Erika Darrah
Förderung
- NIAMS NIH HHS
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Pfizer
Zitieren
APA
Cappelli, L. C., Hines, D., Wang, H., Bingham, C. O., & Darrah, E. (2024). Anti–Peptidylarginine Deiminase 4 Autoantibodies and Disease Duration as Predictors of Treatment Response in Rheumatoid Arthritis. ACR Open Rheumatology, 6(2), 81-90. https://doi.org/10.1002/acr2.11630
Vancouver
Cappelli LC, Hines D, Wang H, Bingham CO, Darrah E. Anti–Peptidylarginine Deiminase 4 Autoantibodies and Disease Duration as Predictors of Treatment Response in Rheumatoid Arthritis. ACR Open Rheumatology. 2024;6(2):81-90. doi:10.1002/acr2.11630
BibTeX
@article{Cappelli2024,
author = {Cappelli, Laura C and Hines, David and Wang, Hong and Bingham, Clifton O and Darrah, Erika},
title = {Anti–Peptidylarginine Deiminase 4 Autoantibodies and Disease Duration as Predictors of Treatment Response in Rheumatoid Arthritis},
journal = {ACR Open Rheumatology},
year = {2024},
volume = {6},
number = {2},
pages = {81--90},
doi = {10.1002/acr2.11630}
}
EUVIMED